Why the study?
Does the measurement of plasma apolipoproteins A-I and B improve the discrimination between healthy individuals and survivors of myocardial infarction compared to HDL- and LDL-cholesterol?
Does the measurement of plasma apolipoproteins A-I and B improve the discrimination between healthy individuals and survivors of myocardial infarction compared to HDL- and LDL-cholesterol?
Standardized measurements of apolipoproteins A-I and B provide better discrimination of post-myocardial infarction patients than standard HDL and LDL cholesterol cutpoints.
The values of apolipoproteins (apo) A-I and B were determined in a population sample of hospital outpatients with a standardized method to verify if the cutpoints calculated in a cross-sectional study in the US are usable with other populations. We also tested the apolipoproteins' ability to discriminate between healthy people and survivors of myocardial infarction. In the studied population the apo A-I value corresponding to the HDL-cholesterol decisional centile is 1.12 g/L for males and 1.17 g/L for females; the apo B value corresponding to the LDL-cholesterol decisional centile is 1.23 g/L for males and 1.14 g/L for females. These values are quite close to the cutpoints proposed for the American population (1.20 g/L for both apolipoproteins). In comparison with the LDL- and HDL-cholesterol decisional concentrations, the cutpoints for apolipoproteins allow a correct classification of a greater percentage of postmyocardial infarction patients (16% higher for apo B and 5% for apo A-I). Standardized assays coupled with a reference database allow a better clinical use of apolipoprotein measurements.
No takes yet. Share an insight, caveat, or question.
Graziani et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Clinical Chemistry